385 related articles for article (PubMed ID: 31911131)
1. Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing.
Li J; Hong S; Chen W; Zuo E; Yang H
J Genet Genomics; 2019 Nov; 46(11):513-521. PubMed ID: 31911131
[TBL] [Abstract][Full Text] [Related]
2. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
[TBL] [Abstract][Full Text] [Related]
3. CRISPR Guide RNA Design Guidelines for Efficient Genome Editing.
Schindele P; Wolter F; Puchta H
Methods Mol Biol; 2020; 2166():331-342. PubMed ID: 32710418
[TBL] [Abstract][Full Text] [Related]
4. Screening of CRISPR/Cas base editors to target the AMD high-risk Y402H complement factor H variant.
Tran MTN; Khalid MKNM; Pébay A; Cook AL; Liang HH; Wong RCB; Craig JE; Liu GS; Hung SS; Hewitt AW
Mol Vis; 2019; 25():174-182. PubMed ID: 30996586
[TBL] [Abstract][Full Text] [Related]
5. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-gRNA Design.
Pallarès Masmitjà M; Knödlseder N; Güell M
Methods Mol Biol; 2019; 1961():3-11. PubMed ID: 30912036
[TBL] [Abstract][Full Text] [Related]
7. Optimization of genome editing through CRISPR-Cas9 engineering.
Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
[TBL] [Abstract][Full Text] [Related]
8. Identifying genome-wide off-target sites of CRISPR RNA-guided nucleases and deaminases with Digenome-seq.
Kim D; Kang BC; Kim JS
Nat Protoc; 2021 Feb; 16(2):1170-1192. PubMed ID: 33462439
[TBL] [Abstract][Full Text] [Related]
9. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.
Kim D; Luk K; Wolfe SA; Kim JS
Annu Rev Biochem; 2019 Jun; 88():191-220. PubMed ID: 30883196
[TBL] [Abstract][Full Text] [Related]
10. Off- and on-target effects of genome editing in mouse embryos.
Ayabe S; Nakashima K; Yoshiki A
J Reprod Dev; 2019 Feb; 65(1):1-5. PubMed ID: 30518723
[TBL] [Abstract][Full Text] [Related]
11. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
Bai B; Myklebust JH; Wälchli S
Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
[TBL] [Abstract][Full Text] [Related]
12. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing.
Naeem M; Majeed S; Hoque MZ; Ahmad I
Cells; 2020 Jul; 9(7):. PubMed ID: 32630835
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 Guide RNA Design Rules for Predicting Activity.
Hiranniramol K; Chen Y; Wang X
Methods Mol Biol; 2020; 2115():351-364. PubMed ID: 32006410
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas systems: ushering in the new genome editing era.
Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
[TBL] [Abstract][Full Text] [Related]
15. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs.
Coelho MA; De Braekeleer E; Firth M; Bista M; Lukasiak S; Cuomo ME; Taylor BJM
Nat Commun; 2020 Aug; 11(1):4132. PubMed ID: 32807781
[TBL] [Abstract][Full Text] [Related]
16. Target-Specific Precision of CRISPR-Mediated Genome Editing.
Chakrabarti AM; Henser-Brownhill T; Monserrat J; Poetsch AR; Luscombe NM; Scaffidi P
Mol Cell; 2019 Feb; 73(4):699-713.e6. PubMed ID: 30554945
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
[TBL] [Abstract][Full Text] [Related]
18. Minimizing off-target effects in CRISPR-Cas9 genome editing.
Chen SJ
Cell Biol Toxicol; 2019 Oct; 35(5):399-401. PubMed ID: 31317359
[No Abstract] [Full Text] [Related]
19. Battling CRISPR-Cas9 off-target genome editing.
Li D; Zhou H; Zeng X
Cell Biol Toxicol; 2019 Oct; 35(5):403-406. PubMed ID: 31313008
[No Abstract] [Full Text] [Related]
20. Computational Analysis Concerning the Impact of DNA Accessibility on CRISPR-Cas9 Cleavage Efficiency.
Chung CH; Allen AG; Sullivan NT; Atkins A; Nonnemacher MR; Wigdahl B; Dampier W
Mol Ther; 2020 Jan; 28(1):19-28. PubMed ID: 31672284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
